Zirconium-89 MK 4464 - Merck Sharp & Dohme
Alternative Names: 89Zr-MK-4464; Zirconium-89-MK-4464Latest Information Update: 02 Sep 2022
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics; Drug conjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 Aug 2022 Preclinical trials in Solid tumours in USA (IV) before August 2022 (NCT05514444)
- 24 Aug 2022 Merck Sharp & Dohme plans a phase I trial for Solid tumour (Metastatic disease, Late-stage diseases, Combination therapy) in Netherland in October 2022 (IV) (NCT05514444)